

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



礼邦医药

Alebund Pharmaceuticals (Jiangsu) Limited

禮邦醫藥（江蘇）股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 09637)

**VOLUNTARY ANNOUNCEMENT
INCLUSION IN THE LIST OF ELIGIBLE SECURITIES FOR
SOUTHBOUND TRADING UNDER STOCK CONNECT AND
IN THE HANG SENG COMPOSITE INDEX**

This announcement is made by Alebund Pharmaceuticals (Jiangsu) Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest development of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that, pursuant to the relevant arrangements and adjustments of the Stock Connect, the H shares of the Company (the “**H Shares**”) have been included in the list of eligible securities for the Stock Connect (“**Stock Connect**”), with effect from September 7, 2026 (Monday). Starting from the effective date, eligible investors in Mainland China may trade the H Shares directly through the relevant Stock Connect mechanism.

The inclusion of the H Shares in the Southbound Trading follows their inclusion in the Hang Seng Composite Index. According to the results of the quarterly review of the Hang Seng Family of Indexes for the quarter ended June 30, 2026 announced by Hang Seng Indexes Company Limited on August 21, 2026, the H Shares have been selected and will be included as a constituent of the Hang Seng Composite Index. The change was implemented after the market close on Friday, September 4, 2026 and will take effect from Monday, September 7, 2026.

The Board believes that the inclusion of the H Shares in the Southbound Trading and the Hang Seng Composite Index reflects the capital markets’ recognition of the Company’s value and long-term development prospects, and will help further broaden the Company’s investor base and enhance the trading liquidity of the H Shares.

ABOUT SHANGHAI-HONG KONG STOCK CONNECT AND SHENZHEN-HONG KONG STOCK CONNECT

Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect are mutual market access programs linking the stock markets in Mainland China and Hong Kong. Through the Southbound Trading, eligible investors in Mainland China may trade eligible securities listed on The Stock Exchange of Hong Kong Limited through local securities firms or brokers.

By order of the Board
Alebund Pharmaceuticals (Jiangsu) Limited
Dr. Gavin Guoyao Xia
*Chairman of the Board, executive Director
and Chief Executive Officer*

Hong Kong, September 4, 2026

As of the date of this announcement, the Board comprises (i) Dr. Gavin Guoyao Xia, Jin Tian, M.D., Ms. Wang Yun and Dr. Zhang Huading as executive Directors; (ii) Dr. Lu An as a non-executive Director; and (iii) Dr. Xu Runhong, Dr. Zhui Chen and Mr. Leung Chi Wai as independent non-executive Directors.